Literature DB >> 29706317

Experience with ceftazidime-avibactam treatment in a tertiary care center in Saudi Arabia.

Abdullah Algwizani1, Mohammad Alzunitan2, Ahmad Alharbi2, Abdulrahman Alsaedy3, Sameera Aljohani4, Bassam Alalwan5, Jawaher Gramish6, Adel Alothman7.   

Abstract

INTRODUCTION: Carbapenem-resistant organisms have become major healthcare-associated pathogens and are responsible for significant morbidity and mortality worldwide. CASES AND MANAGEMENTS: This case-series describes our experience with ceftazidime-avibactam in the treatment of six cases with carbapenem-resistant organisms in King Abdulaziz Medical City in Riyadh, Saudi Arabia. After trying various combinations of antibiotic therapies without improvement, cases were treated with ceftazidime-avibactam. OUTCOMES: Five of the six achieved complete cure, both clinically and microbiologically.
Copyright © 2018 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Ceftazidime–avibactam; MDR-infections; Saudi Arabia

Mesh：

Substances：

Year:  2018        PMID： 29706317     DOI： 10.1016/j.jiph.2018.04.013

Source DB:  PubMed          Journal:  J Infect Public Health        ISSN： 1876-0341            Impact factor:   3.718


  5 in total

Review 1.  Carbapenem-Resistant Gram-Negative Bacterial Infections in Children.

Authors:  David Aguilera-Alonso; Luis Escosa-García; Jesús Saavedra-Lozano; Emilia Cercenado; Fernando Baquero-Artigao
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191

2.  Ceftazidime-Avibactam as Salvage Therapy in Pediatric Liver Transplantation Patients with Infections Caused by Carbapenem-Resistant Enterobacterales.

Authors:  Weili Wang; Rongrong Wang; Yuntao Zhang; Lei Zeng; Haisen Kong; Xueli Bai; Wei Zhang; Tingbo Liang
Journal:  Infect Drug Resist       Date:  2022-06-25       Impact factor: 4.177

Review 3.  Optimal Management of Complicated Infections in the Pediatric Patient: The Role and Utility of Ceftazidime/Avibactam.

Authors:  Matteo Bassetti; Maddalena Peghin; Alessio Mesini; Elio Castagnola
Journal:  Infect Drug Resist       Date:  2020-06-12       Impact factor: 4.003

4.  Ceftazidime-Avibactam versus Colistin for the Treatment of Infections Due to Carbapenem-Resistant Enterobacterales: A Multicenter Cohort Study.

Authors:  Thamer A Almangour; Leen Ghonem; Ahmad Aljabri; Alya Alruwaili; Mohammed Al Musawa; Nader Damfu; Mesfer S Almalki; Majda Alattas; Hossam Abed; Doaa Naeem; Nawaf Almalki; Abdullah A Alhifany
Journal:  Infect Drug Resist       Date:  2022-01-23       Impact factor: 4.003

5.  In vitro activity of ceftazidime/avibactam against clinical isolates of Enterobacterales and Pseudomonas aeruginosa from Middle Eastern and African countries: ATLAS global surveillance programme 2015-18.

Authors:  James A Karlowsky; Samuel K Bouchillon; Ramy El Mahdy Kotb; Naglaa Mohamed; Gregory G Stone; Daniel F Sahm
Journal:  JAC Antimicrob Resist       Date:  2021-06-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.